IL228411A - Cell-permeable iron chlorine n- (1-pyridine-2-il-methylidene) - n- (9h-9,4,3,1- tetra-az-fluorine-2-il) -hydrazine for use in the treatment of solid cancer growth - Google Patents
Cell-permeable iron chlorine n- (1-pyridine-2-il-methylidene) - n- (9h-9,4,3,1- tetra-az-fluorine-2-il) -hydrazine for use in the treatment of solid cancer growthInfo
- Publication number
- IL228411A IL228411A IL228411A IL22841113A IL228411A IL 228411 A IL228411 A IL 228411A IL 228411 A IL228411 A IL 228411A IL 22841113 A IL22841113 A IL 22841113A IL 228411 A IL228411 A IL 228411A
- Authority
- IL
- Israel
- Prior art keywords
- tetraaza
- methylidene
- fluoren
- hydrazine
- pyridine
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 2
- 201000011510 cancer Diseases 0.000 title 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1100201 | 2011-03-21 | ||
| PCT/SE2012/000034 WO2012128689A1 (en) | 2011-03-21 | 2012-03-14 | Treatment of solid tumours |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL228411A0 IL228411A0 (en) | 2013-12-31 |
| IL228411A true IL228411A (en) | 2016-12-29 |
Family
ID=46879602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL228411A IL228411A (en) | 2011-03-21 | 2013-09-12 | Cell-permeable iron chlorine n- (1-pyridine-2-il-methylidene) - n- (9h-9,4,3,1- tetra-az-fluorine-2-il) -hydrazine for use in the treatment of solid cancer growth |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20140073645A1 (enExample) |
| EP (1) | EP2688569B1 (enExample) |
| JP (1) | JP6064215B2 (enExample) |
| KR (1) | KR101937279B1 (enExample) |
| CN (1) | CN103547268B (enExample) |
| AU (1) | AU2012231814B2 (enExample) |
| BR (1) | BR112013024211B1 (enExample) |
| CA (1) | CA2830081C (enExample) |
| DK (1) | DK2688569T3 (enExample) |
| EA (1) | EA025180B1 (enExample) |
| ES (1) | ES2681703T3 (enExample) |
| HU (1) | HUE039021T2 (enExample) |
| IL (1) | IL228411A (enExample) |
| MX (1) | MX2013010770A (enExample) |
| PL (1) | PL2688569T3 (enExample) |
| PT (1) | PT2688569T (enExample) |
| SG (2) | SG10201605083SA (enExample) |
| TR (1) | TR201809040T4 (enExample) |
| WO (1) | WO2012128689A1 (enExample) |
| ZA (1) | ZA201307036B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2900667T3 (da) | 2012-09-21 | 2019-08-26 | Vivolux Ab | Middel og fremgangsmåde til behandling af faste tumorer |
| US12383518B2 (en) | 2013-11-03 | 2025-08-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Disulfide-masked pro-chelator compositions and methods of use |
| US11504346B2 (en) | 2013-11-03 | 2022-11-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Redox-activated pro-chelators |
| CN105807976B (zh) | 2014-12-31 | 2019-02-12 | 清华大学 | 静电传感器 |
| KR20180006916A (ko) * | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| CN104997777A (zh) * | 2015-07-24 | 2015-10-28 | 孔小乐 | 去铁酮的2比1锌络合物作为制备抗癌药物的应用 |
| JP7103745B2 (ja) * | 2015-10-05 | 2022-07-20 | 国立大学法人 岡山大学 | 癌幹細胞抑制剤、癌の転移又は再発の抑制剤並びに癌細胞の未分化マーカー発現抑制剤 |
| PT3390403T (pt) | 2015-12-18 | 2022-09-06 | Vivolux Ab | Composição farmacêutica compreendendo derivados de indole, processo para preparação e uso dos mesmos |
| EP3558282A4 (en) * | 2016-12-21 | 2020-08-12 | The Medical College of Wisconsin, Inc. | SYNERGIC INHIBITION OF TUMOR CELL PROLIFERATION INDUCED BY A THERAPEUTIC ASSOCIATION OF METFORMIN COMPOUNDS AND IRON CHELATORS |
| KR101859922B1 (ko) * | 2017-02-07 | 2018-05-21 | 주식회사 온코크로스 | 클로페네신을 포함하는 대장암 증식 및 전이 억제용 조성물 |
| JP6900067B2 (ja) * | 2017-02-07 | 2021-07-07 | オンコクロス カンパニー，リミテッド | 癌の転移抑制および治療用組成物 |
| CN106831776B (zh) * | 2017-03-16 | 2018-12-07 | 河北科技大学 | 5,10-二氢吡啶并吡嗪并三嗪类化合物及其应用 |
| US11931349B2 (en) * | 2017-11-23 | 2024-03-19 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Iron chelators in tumor therapy |
| CN109646679A (zh) * | 2019-01-28 | 2019-04-19 | 中国科学院长春应用化学研究所 | 铁离子螯合剂及其可药用盐的用途 |
| CN110585194A (zh) * | 2019-10-12 | 2019-12-20 | 广州医科大学附属第五医院 | 倍半萜内酯类化合物在制备溶酶体自噬抑制剂以及抗癌药物中的应用 |
| CA3177830A1 (en) | 2020-05-13 | 2021-11-18 | Maria BECONI | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| CN111849873A (zh) * | 2020-07-30 | 2020-10-30 | 扬州大学 | 一种诱导鸡的胚胎干细胞自噬的方法 |
| WO2025263876A1 (ko) | 2024-06-17 | 2025-12-26 | 서울대학교산학협력단 | Vlx600을 포함하는 항균 또는 항진균용 조성물 및 세균 또는 진균 감염증의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1335686C (fr) * | 1986-01-13 | 1995-05-23 | Rao K. S. P. Bhushana | Vinblastine et composition pharmaceutique les contenant |
| US5480906A (en) * | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
| IL121272A (en) * | 1997-07-10 | 2000-06-01 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia |
| US6660737B2 (en) * | 2001-05-04 | 2003-12-09 | The Procter & Gamble Company | Medicinal uses of hydrazones |
| DE602004031095D1 (de) * | 2003-02-05 | 2011-03-03 | David Benn Lovejoy | Metallionenchelatoren und ihre therapeutische verwendung |
| US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
| AU2005306772A1 (en) * | 2004-11-19 | 2006-05-26 | Shiva Biomedical, Llc | Methods of treating erythropoietin-resistance |
| KR20090007635A (ko) * | 2006-05-09 | 2009-01-19 | 노파르티스 아게 | 철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도 |
| WO2009035534A2 (en) * | 2007-09-07 | 2009-03-19 | The Cleveland Clinic Foundation | Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif) |
| KR101208587B1 (ko) | 2009-06-24 | 2012-12-06 | 여오영 | 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물 |
| DK2900667T3 (da) | 2012-09-21 | 2019-08-26 | Vivolux Ab | Middel og fremgangsmåde til behandling af faste tumorer |
-
2012
- 2012-03-14 US US14/006,277 patent/US20140073645A1/en not_active Abandoned
- 2012-03-14 JP JP2014501035A patent/JP6064215B2/ja active Active
- 2012-03-14 SG SG10201605083SA patent/SG10201605083SA/en unknown
- 2012-03-14 DK DK12760260.5T patent/DK2688569T3/en active
- 2012-03-14 PT PT127602605T patent/PT2688569T/pt unknown
- 2012-03-14 AU AU2012231814A patent/AU2012231814B2/en active Active
- 2012-03-14 EA EA201391286A patent/EA025180B1/ru not_active IP Right Cessation
- 2012-03-14 SG SG2013069729A patent/SG193494A1/en unknown
- 2012-03-14 PL PL12760260T patent/PL2688569T3/pl unknown
- 2012-03-14 HU HUE12760260A patent/HUE039021T2/hu unknown
- 2012-03-14 BR BR112013024211-6A patent/BR112013024211B1/pt not_active IP Right Cessation
- 2012-03-14 MX MX2013010770A patent/MX2013010770A/es active IP Right Grant
- 2012-03-14 TR TR2018/09040T patent/TR201809040T4/tr unknown
- 2012-03-14 WO PCT/SE2012/000034 patent/WO2012128689A1/en not_active Ceased
- 2012-03-14 CA CA2830081A patent/CA2830081C/en active Active
- 2012-03-14 CN CN201280024388.8A patent/CN103547268B/zh active Active
- 2012-03-14 KR KR1020137027532A patent/KR101937279B1/ko active Active
- 2012-03-14 ES ES12760260.5T patent/ES2681703T3/es active Active
- 2012-03-14 EP EP12760260.5A patent/EP2688569B1/en active Active
-
2013
- 2013-09-12 IL IL228411A patent/IL228411A/en active IP Right Revival
- 2013-09-18 ZA ZA2013/07036A patent/ZA201307036B/en unknown
-
2017
- 2017-06-16 US US15/625,337 patent/US10022380B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10022380B2 (en) | 2018-07-17 |
| ZA201307036B (en) | 2014-05-28 |
| EP2688569A4 (en) | 2014-09-10 |
| WO2012128689A1 (en) | 2012-09-27 |
| SG10201605083SA (en) | 2016-08-30 |
| ES2681703T3 (es) | 2018-09-14 |
| KR20140017619A (ko) | 2014-02-11 |
| SG193494A1 (en) | 2013-10-30 |
| CA2830081A1 (en) | 2012-09-27 |
| EP2688569B1 (en) | 2018-05-30 |
| US20170348317A1 (en) | 2017-12-07 |
| CN103547268A (zh) | 2014-01-29 |
| AU2012231814A1 (en) | 2013-09-26 |
| AU2012231814B2 (en) | 2016-06-09 |
| KR101937279B1 (ko) | 2019-01-10 |
| PL2688569T3 (pl) | 2018-09-28 |
| DK2688569T3 (en) | 2018-08-06 |
| MX2013010770A (es) | 2014-03-27 |
| BR112013024211A2 (pt) | 2016-12-20 |
| JP6064215B2 (ja) | 2017-02-01 |
| US20140073645A1 (en) | 2014-03-13 |
| PT2688569T (pt) | 2018-08-06 |
| IL228411A0 (en) | 2013-12-31 |
| BR112013024211B1 (pt) | 2020-12-15 |
| CN103547268B (zh) | 2017-02-22 |
| EP2688569A1 (en) | 2014-01-29 |
| JP2014508804A (ja) | 2014-04-10 |
| TR201809040T4 (tr) | 2018-07-23 |
| EA201391286A1 (ru) | 2014-03-31 |
| CA2830081C (en) | 2020-09-22 |
| EA025180B1 (ru) | 2016-11-30 |
| HUE039021T2 (hu) | 2018-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL228411A (en) | Cell-permeable iron chlorine n- (1-pyridine-2-il-methylidene) - n- (9h-9,4,3,1- tetra-az-fluorine-2-il) -hydrazine for use in the treatment of solid cancer growth | |
| IL276414A (en) | A pyruvate kinase activator for therapeutic use | |
| PL2665749T3 (pl) | Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| ZA201303605B (en) | Compounds and methods for treating pain | |
| IL229876B (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
| HUE060305T2 (hu) | FAP-aktivált proteaszóma inhibitorok a szolid tumorok kezelésére | |
| IL224757A (en) | N- (tetrazole-5-ram) and n- (triazole-5-ram) arylcarboxamides and their use as herbicides | |
| ZA201405298B (en) | A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion | |
| SI2134374T1 (sl) | Inhibitorji btk za rabo pri zdravljenju na kemoterapevtska zdravila rezistentnih epitelijskih tumorjev | |
| HUE059861T2 (hu) | N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra | |
| SI2556071T1 (sl) | Kinazni inhibitorji in njihova uporaba pri zdravljenju raka | |
| HRP20151444T1 (hr) | Sredstva za lijeäśenje i postupci lijeäśenja dlbcl | |
| IL222382A0 (en) | Robo1-fc fusion protein and use thereof for treating tumours | |
| IL227558A0 (en) | A therapeutic agent for tumors | |
| SI2780332T1 (sl) | Morfolinilbenzotriazini za uporabo pri terapiji raka | |
| IL227967A0 (en) | Aminoindene compounds and their use for the treatment of pain | |
| PT2699233T (pt) | Material particulado e toxina celular para utilização no tratamento de um tumor sólido | |
| IL202307A0 (en) | Multikinase inhibitors for use in the treatment of cancer | |
| IL238453A0 (en) | Trans-clomiphene for use in cancer treatment | |
| ZA201209452B (en) | Gold complexes for use in the treatment of cancer | |
| ZA201206898B (en) | Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferatiive disorders | |
| ZA201403574B (en) | Methods for treating gout in patient subpopulations | |
| GB0901465D0 (en) | Compounds for use in therapy | |
| IL228891A (en) | 3-carboxylic salts-n-ethyl n, n-dimethylpropane-1-amine for use in the treatment of cardiovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| MM9K | Patent not in force due to non-payment of renewal fees | ||
| NE | Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967) |